ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Zymeworks Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$25.54+0.51 (+2.04%)

Close on Oct 19, 2026

Market cap: $1.86B
P/E (TTM): –
Dividend yield: –

Zymeworks Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Cash & Equivalents	41	66	158	401	202	242	128
Short-Term Investments	–	–	217	91	51	–	–
Cash & Short-Term Investments	41	66	374	492	253	242	128
Receivables	4.64	56	19	33	16	–	–
Prepaid Expenses & Other	15	19	19	19	20	–	–
Total Current Assets	249	300	413	545	288	–	–
Property, Plant & Equipment	16	18	20	25	23	–	–
Gross Property, Plant & Equipment	36	35	41	38	37	–	–
Accumulated Depreciation	-21	-18	-21	-13	-14	–	–
Long-Term Investments	–	–	82	0.89	0.89	–	–
Operating Lease Right-of-Use Assets	16	17	18	23	27	–	–
Goodwill	12	12	12	12	12	–	–
Intangible Assets	1.35	4.58	7.66	8.76	3.84	–	–
Deferred Tax Assets	4.71	4.39	3.62	1.35	3.07	–	–
Total Assets	347	463	581	649	389	–	–
Accounts Payable	36	60	46	87	63	–	–
Current Portion of Leases	3.47	2.74	4.26	3.32	1.31	–	–
Current Income Taxes Payable	0.08	0.13	1.81	0.84	0	–	–
Deferred Revenue (Current)	2.42	26	3.70	2.35	0	–	–
Other Current Liabilities	–	–	–	–	0.02	–	–
Total Current Liabilities	42	88	56	96	72	–	–
Long-Term Leases	15	16	22	25	31	–	–
Operating Lease Liabilities	18	18	27	28	32	–	–
Deferred Tax Liabilities	6.03	4.76	3.30	1.79	1.57	–	–
Other Long-Term Liabilities	0.28	0.92	1.70	3.10	2.75	–	–
Total Liabilities	78	124	116	156	140	–	–
Preferred Stock	0	0	0	0	0	–	–
Common Stock	1,105	1,016	997	886	741	–	–
Additional Paid-In Capital	115	152	142	152	198	–	–
Retained Earnings	-953	-830	-677	-559	-683	–	–
Comprehensive Income & Other	-6.08	-6.95	-6.60	-6.66	-6.66	–	–
Shareholders' Equity	269	339	465	493	249	410	246
Total Equity	269	339	465	493	249	410	246
Total Liabilities & Equity	347	463	581	649	389	–	–
Shares Outstanding(shares)	75	69	70	63	47	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -419.0%
Net margin: -404.0%
Return on equity, FY2025: -26.7%

Financial strength

Current ratio: 6.32
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 379.8%

Valuation

P/E ratio: –
Price to sales: 50.21
Price to book: 23.20
Dividend yield: –